Share ownership Guardant Health, Inc.

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 01:27:47 2026-03-09 pm EDT			5-day change	1st Jan Change
88.62 ^USD	-2.83%		-3.38%	-12.76%

Mar. 05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI

Share class: Guardant Health, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	123,554,612	117,918,590 ( 95.44 %)	0	95.44 %

Major shareholders: Guardant Health, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.4 %	12,160,768	9.4 %	1 387 M $
BlackRock Advisors LLC 7.916 %	10,240,933	7.916 %	1 168 M $
T. Rowe Price International Ltd. 4.356 %	5,636,078	4.356 %	643 M $
Invesco Advisers, Inc. 4.109 %	5,315,934	4.109 %	606 M $
Baillie Gifford & Co. 3.78 %	4,890,026	3.78 %	558 M $
Capital Research & Management Co. (International Investors) 2.727 %	3,528,656	2.727 %	402 M $
Fiduciary Trust Company International 2.598 %	3,361,547	2.598 %	383 M $
Geode Capital Management LLC 2.484 %	3,213,657	2.484 %	366 M $
Deep Track Capital LP 2.164 %	2,800,000	2.164 %	319 M $
STATE STREET CORPORATION 2.161 %	2,795,727	2.161 %	319 M $
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	88.22%
Other	10.32%
Individuals	3.8%
State Street Corp.	2.16%
Sumitomo Mitsui Trust Group, Inc.	0.5%
Manulife Financial Corp.	0.49%
SEI Investments Co.	0.25%
Schweizerische Nationalbank	0.17%
Rathbones Group Plc	0.16%
Polar Capital Holdings Plc	0.12%
Baader Bank AG	0.01%
Governments	0.01%
Banque Cantonale Vaudoise	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	82.18%
United Kingdom	13.23%
Individuals	3.8%
Canada	1.41%
Norway	0.99%
Austria	0.82%
Singapore	0.82%
Japan	0.61%
Germany	0.47%
Czech Republic	0.36%
Switzerland	0.33%
Denmark	0.31%
Luxembourg	0.3%
Australia	0.19%
France	0.1%
Sweden	0.09%
Ireland	0.08%
Netherlands	0.04%
Cayman Islands	0.02%
China	0.02%
Finland	0.01%
Hong Kong	0.01%
Poland	0.01%
Italy	0.01%
South Korea	0.01%
Taiwan	0.01%

Based on 1000 largest holdings

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,498

Sector

Medical Equipment, Supplies & Distribution

More about the company